Disease · MONDO_0004949
Trials37
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 37
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | Phase 2 | 135 | 2018-07-24 | Lymphoma, B-cell Lymphoma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | CYCLOPHOSPHAMIDE, FLUDARABINE, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | Phase 1/2 | 119 | 2012-09-18 | Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia | GEMCITABINE HYDROCHLORIDE, PRALATREXATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01980628 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma | Phase 2 | 63 | 2017-02-10 | Marginal Zone Lymphoma, B-cell Lymphoma | IBRUTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03520920 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | Phase 2 | 41 | 2021-10-28 | Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma | RITUXIMAB, ZANUBRUTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00453102 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma | Phase 2 | 18 | 2016-01-01 | Marginal Zone Lymphoma | IBRITUMOMAB TIUXETAN, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | Phase 1/2 | 14 | 2021-07-08 | B-cell Lymphoma, Chronic Lymphocytic Leukaemia, Waldenström Macroglobulinemia | BI-1206, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | Phase 2 | 11 | 2015-05-07 | Follicular Lymphoma, Marginal Zone Lymphoma | AZACITIDINE, LENALIDOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03269552 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma | Phase 2 | 4 | 2020-01-18 | Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia | CARFILZOMIB, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | 2 | 2022-09-19 | Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma | ACALABRUTINIB, CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | Phase 2/3 | 710 | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma | BENDAMUSTINE, UBLITUXIMAB, UMBRALISIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02945215 | A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients | Phase 1 | 181 | B-Cell Lymphoma | RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03276468 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | Phase 2 | 136 | Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue | ATEZOLIZUMAB, OBINUTUZUMAB, VENETOCLAX | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03664297 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | Phase 1 | 86 | Mature B Cell Neoplasms | EDRALBRUTINIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00138086 | Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma | Phase 2 | 75 | B-Cell Lymphoma | IBRITUMOMAB TIUXETAN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | Phase 1 | 72 | Acute Myelogenous Leukemia, B-cell Lymphoma | ALDESLEUKIN, BENDAMUSTINE, CYCLOPHOSPHAMIDE, FLUDARABINE, OBINUTUZUMAB, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05014100 | Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma | Phase 2 | 55 | B-cell Lymphoma | LENALIDOMIDE, ORELABRUTINIB, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03424122 | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | Phase 1 | 50 | B-cell Lymphoma | BENDAMUSTINE, IBRUTINIB, PARSACLISIB, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03804996 | Study of TG-1801 in Subjects With B-Cell Lymphoma | Phase 1 | 50 | B-Cell Lymphoma | ZERIPATAMIG | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | Phase 2 | 43 | Non-Hodgkin's Lymphoma, Marginal Zone Lymphoma | GEMCITABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02395601 | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | Phase 1 | 41 | B-Cell Lymphoma | CPI-1205 | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004949/trials